Comparison of ceftizoxime and cefazolin in respiratory tract infection -the first report: Ceftizoxime 4g vs cefazolin 4g (double blind study)

Kenzo Shiota, Fumio Miki, Tomokazu Asai, Kenji Kubo, Kenji Takamatsu, Masakazu Kohno, Yasumichi Kato, Akira Saito, Ichiro Nakayama, Masumi Tomizawa, Yoshio Kinoshita, Katsuhiko Matsui, Yoshinobu Takashiro, Utsuru Miwa, Hideo Hosoya, Morikuni Abe, Hiroyuki Kumano, Akira Ujiie, Akira Sagawa, Mikihiko TangoFumio Nagahama, Takehito Nakabayashi, Takahisa Saito, Shun Fujimoto, Kazuo Takebe, Yoshihiro Kumasaka, Hisashi Nakahata, Kenichi Imamura, Tsuneharu Baba, Seiichi Murakami, Osamu Uehara, Shuichiro Yoshida, Yasuhiro Kawabe, Gen Inaoka, Masashige Kobayashi, Masafumi Kitaoka, Hideaki Kashiwamura, Tamotsu Takishima, Sumio Arai, Kiyoshi Konno, Kotaro Oizumi, Akira Watanabe, Seiichi Aonuma, Kunio Imataka, Kenichi Okayama, Masataka Katsu, Keimei Mashimo, Sumio Yamaoka, Otohiko Kunii, Kazufuto Fukaya, Keiichi Nakagawa, Yoshiaki Kawaguchi, Hiroaki Nakazawa, Kentaro Watanabe, Masaru Koyama, Yasushi Ueda, Fumio Matsumoto, Atsushi Saito, Hiroyuki Kobayashi, Hideo Ikemoto, Kazuyoshi Watanabe, Kaoru Shimada, Junzaburo Kabe, Mikihisa Suehara, Hiroyoshi Ishibashi, Yutaka Hayakawa, Yoshio Kobayashi, Ippei Fujimori, Hajimu Takeda, Fusanosuke Yamasaku, Yasutoshi Suzuki, Osamu Sekine, Yoshimaru Usuda, Nobuki Aoki, Yasuko Yuasa, Toshiyuki Yamamoto, Masahito Kato, Hirohiko Nagasaka, Kozo Mori, Saburo Kitaura, Kunio Nanjo, Joichi Kato, Toshihiko Takeuchi, Teruo Katayama, Takashi Kobayashi, Yoshihiro Senda, Keiko Kamiya, Mitsuru Iwakura, Nobuyoshi Mizutani, Takahiro Tsujimoto, Kenichi Shimizu, Rinzo Soejima, Toshiharu Matsushima, Yoshihiko Tano, Yoshihito Niki, Kazuaki Takeuchi, Osamu Kurimura, Kazue Sadamotc, Hideo Sasaki, Tsuneo Ishibashi, Masahiro Takamoto, Kohei Hara, Masao Nakatomi, Masaru Nasu, Kinichi Izumikawa, Yoshiteru Shigeno, Rokushi Oka, Hisashi Ishikawa, Hiromaru Iwasaki, Takeshi Ishizaki, Tsuneo Tsutsumi, Noriaki Nakamura, Kkimitsu Tomonaga, Keizo Matsumoto, Harumi Shishido, Haruhiko Toxuomi, Masayuki Ando, Katsumasa Tokunaga, Yasutsugu Fukuda, Yoshio Takaba, Mamoru Akatsuka, Kazuo Ishizaka, Yasumasa Hiro, Tatsuo Tomita, Haruo Nozute, Ryuji Kaki, Shinobu Takenaka, Kenji Shimomura

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    The therapeutic efficacy, adverse reactions and usefulness of ceftizoxime (FK 749, CZX) were objectively compared with those of cefazolin (CEZ) in 228 patients with pneumonia or chronic respiratory tract infection in a double-blind comparative study at 31 institutions in Japan. Patients were given daily 4 g of ceftizoxime or cefazolin in 2 divided doses by i. v. drip infusion for, in principle, 14 days. The results were as follows: 1) No significant difference was observed between the therapeutic efficacy of ceftizoxime 4g/day and that of cefazolin 4 g/day. 2) The improvement in chest rale in patients with pneumonia or lung abscess was significantly better in the ceftizoxime group than in the cefazolin group on the 3 rd day of dosing. The improvement in CRP was significantly better in the cefazolin group than in the ceftizoxime group on the 14 th day of dosing. The improvement in erythrocyte sedimentation rate of patients with respiratory tract infection except pneumonia and lung abscess was significantly better in the ceftizoxime group than in the cefazolin group on the 3 rd day. 3) No significant difference was observed between the two drug groups in bacteriological efficacy against causative organisms isolated from patients. 4) Significant differences were noted between the two drug groups in incidence of side effects; fever occurred in many patients of the ceftizoxime group (Fever was attributed to contamination by trace amounts of impurities). 5) No significant difference in usefulness was observed between the two drug groups. These findings suggest that the therapeutic efficacy of ceftizoxime 4 g/day was almost the same as that of cefazolin 4 g/day, but it was impossible to compare accurately the efficacy and safety of ceftizoxime with those of cefazolin because fever not attributable to ceftizoxime occured very frequently.

    Original languageEnglish
    Pages (from-to)939-993
    Number of pages55
    JournalChemotherapy
    Volume29
    Issue number9
    DOIs
    Publication statusPublished - 1981

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Comparison of ceftizoxime and cefazolin in respiratory tract infection -the first report: Ceftizoxime 4g vs cefazolin 4g (double blind study)'. Together they form a unique fingerprint.

  • Cite this

    Shiota, K., Miki, F., Asai, T., Kubo, K., Takamatsu, K., Kohno, M., Kato, Y., Saito, A., Nakayama, I., Tomizawa, M., Kinoshita, Y., Matsui, K., Takashiro, Y., Miwa, U., Hosoya, H., Abe, M., Kumano, H., Ujiie, A., Sagawa, A., ... Shimomura, K. (1981). Comparison of ceftizoxime and cefazolin in respiratory tract infection -the first report: Ceftizoxime 4g vs cefazolin 4g (double blind study). Chemotherapy, 29(9), 939-993. https://doi.org/10.11250/chemotherapy1953.29.939